These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26758806)

  • 1. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
    Raman MC; Rizkallah PJ; Simmons R; Donnellan Z; Dukes J; Bossi G; Le Provost GS; Todorov P; Baston E; Hickman E; Mahon T; Hassan N; Vuidepot A; Sami M; Cole DK; Jakobsen BK
    Sci Rep; 2016 Jan; 6():18851. PubMed ID: 26758806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
    Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
    Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
    Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
    Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
    Stone JD; Harris DT; Kranz DM
    Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
    Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
    J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
    Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
    J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.
    Simon P; Omokoko TA; Breitkreuz A; Hebich L; Kreiter S; Attig S; Konur A; Britten CM; Paret C; Dhaene K; Türeci Ö; Sahin U
    Cancer Immunol Res; 2014 Dec; 2(12):1230-44. PubMed ID: 25245536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
    Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
    J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.
    Soon CF; Zhang S; Suneetha PV; Antunes DA; Manns MP; Raha S; Schultze-Florey C; Prinz I; Wedemeyer H; Sällberg Chen M; Cornberg M
    Front Immunol; 2019; 10():2076. PubMed ID: 31552033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
    Jaigirdar A; Rosenberg SA; Parkhurst M
    J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.
    Schmid DA; Irving MB; Posevitz V; Hebeisen M; Posevitz-Fejfar A; Sarria JC; Gomez-Eerland R; Thome M; Schumacher TN; Romero P; Speiser DE; Zoete V; Michielin O; Rufer N
    J Immunol; 2010 May; 184(9):4936-46. PubMed ID: 20351194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
    Linette GP; Stadtmauer EA; Maus MV; Rapoport AP; Levine BL; Emery L; Litzky L; Bagg A; Carreno BM; Cimino PJ; Binder-Scholl GK; Smethurst DP; Gerry AB; Pumphrey NJ; Bennett AD; Brewer JE; Dukes J; Harper J; Tayton-Martin HK; Jakobsen BK; Hassan NJ; Kalos M; June CH
    Blood; 2013 Aug; 122(6):863-71. PubMed ID: 23770775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass Spectrometry.
    Merkle PS; Trabjerg E; Hongjian S; Ferber M; Cuendet MA; Jørgensen TJD; Luescher I; Irving M; Zoete V; Michielin O; Rand KD
    Biochemistry; 2021 Mar; 60(11):859-872. PubMed ID: 33689297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
    Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
    Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic analysis of the combinatorial nature of epitopes recognized by TCR leads to identification of mimicry epitopes for glutamic acid decarboxylase 65-specific TCRs.
    Uemura Y; Senju S; Maenaka K; Iwai LK; Fujii S; Tabata H; Tsukamoto H; Hirata S; Chen YZ; Nishimura Y
    J Immunol; 2003 Jan; 170(2):947-60. PubMed ID: 12517961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
    Simister PC; Border EC; Vieira JF; Pumphrey NJ
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational melding permits a conserved binding geometry in TCR recognition of foreign and self molecular mimics.
    Borbulevych OY; Piepenbrink KH; Baker BM
    J Immunol; 2011 Mar; 186(5):2950-8. PubMed ID: 21282516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific roles of each TCR hemichain in generating functional chain-centric TCR.
    Nakatsugawa M; Yamashita Y; Ochi T; Tanaka S; Chamoto K; Guo T; Butler MO; Hirano N
    J Immunol; 2015 Apr; 194(7):3487-500. PubMed ID: 25710913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single TCR alpha-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire.
    Liang X; Weigand LU; Schuster IG; Eppinger E; van der Griendt JC; Schub A; Leisegang M; Sommermeyer D; Anderl F; Han Y; Ellwart J; Moosmann A; Busch DH; Uckert W; Peschel C; Krackhardt AM
    J Immunol; 2010 Feb; 184(3):1617-29. PubMed ID: 20042572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.